The global immunotoxins market is anticipated to reach USD 243.3 million by 2030 and is anticipated to expand at a CAGR of 8.08% from 2024 to 2030. The rising prevalence of cancer and technological advancements are some of the factors anticipated to drive market growth.
Immunotoxins are a class of targeted therapeutics that combine a cytotoxic agent with a targeting moiety, such as an antibody or growth factor. The development of immunotoxins has gained momentum due to their potential effectiveness in treating various cancers and other diseases. Cancer is a growing concern worldwide, with an estimated 20 million new cases and 9.7 million deaths in 2022. Immunotoxins consist of an antibody fragment, or a targeting moiety linked to a toxin, which allows for selective delivery of the toxic agent directly to cancer cells. Moreover, the development and application of immunotoxins have evolved significantly over recent years, leading to various ongoing research initiatives aimed at improving their efficacy, reducing immunogenicity, and expanding their therapeutic applications. Researchers are identifying novel tumor-specific antigens that could serve as targets for new immunotoxin therapies.
The COVID-19 pandemic led to significant disruptions in global supply chains. Manufacturing facilities faced shutdowns or reduced operations due to health regulations and workforce shortages. This situation affected the availability of raw materials and components necessary for producing immunotoxins. Moreover, the pandemic fostered collaboration among pharmaceutical companies, academic institutions, and government entities to accelerate drug development processes, further propelling market growth.
However, one of the primary challenges associated with immunotoxin therapies is the potential for severe side effects. Patients may experience adverse reactions such as nausea, diarrhea, and fever. For instance, certain toxins like Ricin-based immunotoxins have been associated with severe complications such as capillary leak syndrome or hepatotoxicity. Such risks can lead to clinical trial terminations or regulatory hurdles during drug approval processes, further limiting market growth.
This product will be delivered within 2 business days.
Immunotoxins are a class of targeted therapeutics that combine a cytotoxic agent with a targeting moiety, such as an antibody or growth factor. The development of immunotoxins has gained momentum due to their potential effectiveness in treating various cancers and other diseases. Cancer is a growing concern worldwide, with an estimated 20 million new cases and 9.7 million deaths in 2022. Immunotoxins consist of an antibody fragment, or a targeting moiety linked to a toxin, which allows for selective delivery of the toxic agent directly to cancer cells. Moreover, the development and application of immunotoxins have evolved significantly over recent years, leading to various ongoing research initiatives aimed at improving their efficacy, reducing immunogenicity, and expanding their therapeutic applications. Researchers are identifying novel tumor-specific antigens that could serve as targets for new immunotoxin therapies.
The COVID-19 pandemic led to significant disruptions in global supply chains. Manufacturing facilities faced shutdowns or reduced operations due to health regulations and workforce shortages. This situation affected the availability of raw materials and components necessary for producing immunotoxins. Moreover, the pandemic fostered collaboration among pharmaceutical companies, academic institutions, and government entities to accelerate drug development processes, further propelling market growth.
However, one of the primary challenges associated with immunotoxin therapies is the potential for severe side effects. Patients may experience adverse reactions such as nausea, diarrhea, and fever. For instance, certain toxins like Ricin-based immunotoxins have been associated with severe complications such as capillary leak syndrome or hepatotoxicity. Such risks can lead to clinical trial terminations or regulatory hurdles during drug approval processes, further limiting market growth.
Immunotoxins Market Report Highlights
- Based on product, the Diphtheria Toxin (DT) segment held the largest market share of 43.96% in 2023. DT-based immunotoxins are highly effective in targeting specific cancer cells, making them valuable for treating cancers that are resistant to standard therapies like chemotherapy and radiation. On the other hand, Pseudomonas Exotoxin (PE) is anticipated to grow at a significant CAGR over the forecast period.
- Based on application, in 2023, therapy development segment is anticipated to dominate the market share for the application segment and is anticipated to grow at the fastest CAGR over the forecast period.
- Based on end-use, pharmaceutical & biotechnology companies segment dominated the end use segment with the largest share of 46.40% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period. However, on the other hand, academic institutes is anticipated to grow at a significant CAGR over the forecast period.
- Based on region, North America region dominated the market with a share of 41.41% owing to factors such as strong R&D in biotechnology, medicine, and therapeutics, along with substantial government funding. Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period.
The leading players in the Immunotoxins market include:
- Creative Biolabs.
- List Biological Labs, Inc.
- The Native Antigen Company
- Bio-Techne.
- Abcam Plc.
- CAYMAN CHEMICAL
- Merck KGaA
- Enzo Life Sciences, Inc.
- Santa Cruz Biotechnology, Inc.
- Quadratech Diagnostics Ltd.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Immunotoxins Market Variables, Trends & Scope
Chapter 4. Immunotoxins Market: Product Estimates & Trend Analysis
Chapter 5. Immunotoxins Market: Application Estimates & Trend Analysis
Chapter 6. Immunotoxins Market: End Use Estimates & Trend Analysis
Chapter 7. Immunotoxins Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players in the Immunotoxins market include:- Creative Biolabs.
- List Biological Labs, Inc.
- The Native Antigen Company
- Bio-Techne.
- Abcam Plc.
- CAYMAN CHEMICAL
- Merck KGaA
- Enzo Life Sciences, Inc.
- Santa Cruz Biotechnology, Inc.
- Quadratech Diagnostics Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 142.6 Million |
| Forecasted Market Value ( USD | $ 243.3 Million |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
